The 2023 IVI Annual Meeting is the formal convening of IVI members to engage in productive and action-focused discussions that will inform and influence how value is defined in healthcare. This conference provides excellent opportunities to connect with other visionaries and gain a deeper understanding of the potential and challenges facing equitable health technology assessment today, tomorrow, and beyond.
Patient Advocate and Student Travel Stipend: IVI is pleased to offer travel stipends for patient advocate and student members. Applications must be submitted via the link provided by August 1, 2023. We will notify applicants by August 15, 2023.
Sponsorship Prospectus: View the current Annual Meeting sponsorship prospectus here.
Exclusive Event: The IVI Annual Meeting is an invitation only event. Invitations will be sent individually. IVI has membership options at the personal and institutional level. Become a member now to join us in September.
The 2023 IVI Annual Meeting will take place at The Westin Alexandria Old Town in Alexandria, Virginia.
Agenda
Monday, September 18 — Public Event
A public event with opening remarks from Jason Spangler, MD, MPH, FACPM, IVI Chief Executive Officer.
Tuesday, September 19 — Members Only Event
- Overview of Meeting Agenda and Goals
- Introductions
Speakers:
- Jason Spangler, MD, MPH, FACPM (Chief Executive Officer, Innovation and Value Initiative)
- Michael Thompson (Chair, IVI Board of Directors)
- Thought Leadership Discussion
- Audience Q&A
Speakers:
- Jason Spangler, MD, MPH, FACPM (Chief Executive Officer, Innovation and Value Initiative)
- Rhonda Robinson Beale, MD (Chief Medical Officer, Mental Health Services, UnitedHealth Group )
The Open-Source Value Project is a platform for IVI to test, demonstrate, and operationalize novel economic modeling methods and practices in health technology assessment. After three years of continual engagement with our 20-member multi-stakeholder advisory group, we are launching the much anticipated open-source IVI-MDD value model for public comment.
This symposium will convene our research partners and advisors to reflect on how patient input and multi-stakeholder insights have informed the model’s development, as well as explore applications of the model to improve equitable patient-centered care.
Speakers:
- Moderator: Richard Xie, PhD (Innovation and Value Initiative)
- Michael Mersky (OPEN Health)
- Warren Stevens, PhD (Medicus Economics)
- Bruny Kenou (George Washington School of Medicine and Health Sciences)
A principal IVI role is convening diverse stakeholders to explore action that improves the science and practice of HTA. The Health Equity Initiative and Economic Impacts Project have yielded frameworks and tangible examples of actionable change to put the needs and perspectives of people with lived experience at the forefront of measuring value. This panel discussion will explore the impact of IVI’s work for patients, researchers, industry, and policymakers, and consider next steps for further change.
Speakers:
- Moderator: Elridge Proctor, MPA (GO2 for Lung Cancer)
- Olivia G. Dieni, MPH (Cystic Fibrosis Foundation)
- Nicole Boschi, PhD (National Multiple Sclerosis Society)
- Kate Davidson, LCSW (Center for Medicare and Medicaid Innovation)
Value, pricing, reimbursement, and HTA are increasingly prominent topics in U.S. policy discussions on new health innovations. Most recently, these debates have largely centered on CMS’s implementation of the Medicare drug price negotiation provisions of the Inflation Reduction Act. This panel will identify key considerations for implementation of the IRA, discuss the broader issues raised by IRA implementation, and explore opportunities for IVI’s work to inform ongoing policy discussions.
Speakers:
- Moderator: Mark Linthicum, MPP (Innovation and Value Initiative)
- Karen Mancera-Cuevas, DrPH, MPH, MS (National Health Council)
- Barry Liden, JD (University of Southern California)
- Daniel Heider (Centers for Medicare and Medicaid Services)
Carolyn Clancy, MD from the Veteran’s Administration will be this year’s keynote speaker.
IVI has convened a group of experts across patient and family, research, and healthcare communities in a series of roundtables to discuss the feasibility of finding common and cross-cutting patient-centered outcomes in rare diseases. This panel will feature speakers from different stakeholder perspectives to discuss prioritized areas for improving data and methods to better serve patient needs in rare diseases.
Speakers:
- Moderator: Rick Chapman, PhD (Innovation and Value Initiative)
- Karin Hoelzer, DVM, PhD (National Organization for Rare Disorders)
- Tamar Thompson, MS (Alexion)
Value and quality are two key characteristics we all want in healthcare, but very little has been said about how they relate to each other. This session will address the interactions between the two and how integrating them will improve both and lead to a better and more patient-centered healthcare system.
Speakers:
- Jason Spangler, MD, MPH, FACPM (Innovation and Value Initiative)
- Richard Schmitz, MA (Pharmacy Quality Alliance)
- Norris Turner, PharmD, PhD (Turner Healthcare Quality Consulting)
- Gretchen Wartman (National Minority Quality Forum)
As part of IVI’s Valuing Innovation Project, a Call for Papers went out in early 2023 to identify practical solutions to better define and measure the innovative properties of health technologies. This panel will feature a facilitated discussion on next steps to incorporate these novel approaches into HTA frameworks.
Speakers:
- Moderator: Rick Chapman, PhD (Innovation and Value Initiative)
- Anna Hyde, MA (Arthritis Foundation)
IVI’s Chief Executive Officer, Jason Spangler, MD, MPH, FACPM, will share his closing remarks as we conclude the event.
If you have any questions about the event, invitations, or becoming a member, please reach out to Jessica Brown ([email protected]) or click the button below.
Speakers
Nicole Boschi
National Multiple Sclerosis Society
Nicole Boschi, PhD
Nicole M. Boschi, PhD is the Director of Regulatory Affairs at the National Multiple Sclerosis Society. In this role, she works to build relationships with federal agencies to achieve a world free of MS. Dr. Boschi received her B.S. (cum laude) in Neuroscience from the University of Rochester and her M.S. and Ph.D. in pharmacology from the University of Rochester Medical Center. Her research on tyrosine hydroxylase has been published in the journal Neuroscience. She is the recipient of the Harold C. Hodge Fellowship at the University of Rochester Medical Center and the Young Advocate Award from the Society for Neuroscience. Dr. Boschi’s professional interests include mitigating health disparities so that all individuals have access to high-quality healthcare.
Rick Chapman
Innovation and Value Initiative
Rick Chapman, PhD
Rick Chapman brings decades of health economics and outcomes research (HEOR) expertise to his role as Chief Science Officer. Chapman was Director of Health Economics at the Institute for Clinical and Economic Review prior to IVI, where he led development of economic evaluations that accompanied rigorous reviews of clinical evidence. Formerly, he was VP of HEOR at Avalere Health. Before that, Chapman was a principal in HEOR at IMS Health, and a research analyst at the Center for Risk Analysis at the Harvard School of Public Health.
Chapman holds a PhD in health policy with a concentration in decision sciences from Harvard University. He also holds an MS in health policy and management from the Harvard School of Public Health.
Carolyn Clancy
Veterans Health Administration
Carolyn Clancy, MD, MACP
Dr. Clancy serves as the Assistant Under Secretary for Health (AUSH) for Discovery, Education & Affiliate Networks (DEAN), Veterans Health Administration (VHA), effective July 22, 2018. The Office of the DEAN fosters collaboration and knowledge transfer with facility-based educators, researchers and clinicians within VA, and between VA and its affiliates.
Prior to her current position, she served as the Acting Deputy Secretary of the Department of Veterans Affairs, the second-largest Cabinet department, with a $246 billion budget and over 424,000 employees serving in VA medical centers, clinics, benefits offices, and national cemeteries, overseeing the development and implementation of enterprise-wide policies, programs, activities and special interests. She also served as the VHA Executive in Charge, with the authority to perform the functions and duties of the Under Secretary for Health, directing a health care system with a $68 billion annual budget, overseeing the delivery of care to more than 9 million enrolled Veterans. Previously, she served as the Interim Under Secretary for Health from 2014-2015. Dr. Clancy also served as the VHA AUSH for Organizational Excellence, overseeing VHA’s performance, quality, safety, risk management, systems engineering, auditing, oversight, ethics and accreditation programs, as well as ten years as the Director, Agency for Healthcare Research and Quality.
She is a highly experienced and nationally recognized physician executive. Dr. Clancy is a general internist and health services researcher, a graduate of Boston College and the University of Massachusetts Medical School. She holds an academic appointment at George Washington University’s School of Medicine and serves as Senior Associate Editor, Health Services Research Journal. She has contributed to eight academic textbooks and authored, co-authored and provided invited commentary in more than 225 scholarly journal articles. She served as member of the National Quality Forum’s Board of Directors, Chair of the AQA Alliance and served on the Board of Governors for the Patient-Centered Outcomes Research Institute. She is an elected member of the National Academy of Medicine and was presented with the 2014 Quality Champion Award from the National Committee for Quality Assurance. She was also named as an Honorary Fellow of the American Academy of Nursing and was selected as the 2015 Outstanding Federal Executive of the Year by Disabled American Veterans. In 2018, she was selected as one of the Top 50 Physician Executives by Modern Healthcare, and in 2019, she was identified as one of the 50 Most Influential Clinical Executives by Modern Healthcare. And she was also awarded the 2023 Primary Care Collaborative’s (PCC) prestigious Barbara Stanfield Award.
Kate Davidson
CMS/CMMI
Kate Davidson, LCSW
Kate Davidson, LCSW is the Director of the Learning and Diffusion Group (LDG) at the Center for Medicare and Medicaid Innovation, within the Centers for Medicare & Medicaid Services (CMS). In this role, Ms. Davidson leads the Innovation Center’s team focused on accelerating healthcare system transformation and person-centeredness by leveraging improvement science within and across models. She also executes on the Innovation Center’s strategy for multi-payer alignment through the Healthcare Payment Learning and Action Network (HCP-LAN). Prior to joining CMS, Ms. Davidson led Policy and Practice Improvement efforts at the National Council for Mental Wellbeing, where she managed payment reform, quality improvement and workforce development initiatives in mental health and addiction prevention, treatment, and recovery organizations and provided training and technical assistance to healthcare and human services organizations, counties and states. Ms. Davidson began her career researching, testing and scaling interventions in healthcare and community-based settings. In this capacity she has provided clinical and administrative leadership in a broad range of settings testing innovative payment and care delivery models. Ms. Davidson has an MSW from Fordham University and a BA from Loyola College in Maryland.
Olivia Dieni
Cystic Fibrosis Foundation
Olivia Dieni, MPH
Daniel Heider
Centers for Medicare and Medicaid Services
Daniel Heider
Daniel Heider is the Director in the Division of Rebate Agreements and Drug Pricing Negotiations, MDRNG at the Center for Medicare and Medicaid Services. In this role, Daniel leads a team responsible for developing the methodology, processes and timelines for maximum fair price negotiations with pharmaceutical manufacturers for Part D and B drugs selected for negotiation and renegotiation under the Inflation Reduction Act. He also reviews and evaluates regulations, guidance, and instructions required for the dissemination of policies and stakeholders related to the work of the Division. Prior to joining CMS, Daniel oversaw the pricing decisions, strategies, and initiatives at Bristol-Meyers Squibb as the Senior Director, WW Lead Cardiovascular, Immunology, Fibrosis Strategy & Execution and as the Director of Global Pricing at Merck. Daniel holds an MA in Applied Economics from the Johns Hopkins University.
Karin Hoelzer
National Organization for Rare Disorders
Karin Hoelzer, DVM, PhD
Dr. Karin Hoelzer directs Policy and Regulatory Affairs for the National Organization for Rare Disorders (NORD®). In this role, Karin provides strategic direction to advance NORDs federal policy and regulatory priorities. She works closely with key rare disease partners across the pharmaceutical and biological space to ensure the policy landscape supports innovative approaches and new treatments to help rare disease patients, and adequately incorporates patient preferences and perspectives in therapy development. Her role also involves extensive legislative and communication engagements to advance rare disease policy priorities.
Dr. Hoelzer is a health policy, risk analysis, and biomedical research expert, with extensive intellectual property and regulatory expertise across most FDA-regulated products. Most recently, she worked at Maximus, Inc. where she established and led a new health data analytics division to provide more timely data and better insights to government clients in support of the public health response to the COVID-19 pandemic.
Prior to working at Maximus, Inc., Dr. Hoelzer served as Senior Officer for Health Programs at The Pew Charitable Trusts where she led policy and regulatory efforts to improve the federal oversight of a variety of FDA-regulated products. Dr. Hoelzer joined Pew from the Food and Drug Administration (FDA), where she served as Risk Analyst. In this role, she assessed and quantified the expected impact of changes to FDA policy and regulatory practice.
Prior to joining FDA in 2010, Dr. Hoelzer worked as Biomedical Researcher for Cornell University. She received a PhD in comparative biomedical sciences from Cornell University and a Doctor of Veterinary Medicine degree from the University of Veterinary Medicine in Hannover (Germany). Since 2014, she is also a registered patent agent with the U.S. Patent and Trademark Office, and remains active in the biomedical research space. This includes serving as Editor in Chief for a major peer-reviewed international biomedical research journal and as the Executive Director for the professional association representing veterinarians in DC.
Anna Hyde
Arthritis Foundation
Anna Hyde, MA
Anna Hyde is the Vice President of Advocacy and Access at the Arthritis Foundation. She oversees both the federal and state legislative programs, in addition to grassroots engagement. Her focus is to raise the visibility of arthritis as a public health priority, build support for federal and state legislation that ensure access to affordable, high-quality health care, and enhance patient engagement in the policy-making process. Anna previously served as Senior Director of Advocacy and Access, managing the federal affairs portfolio and overseeing the state advocacy team.
Prior to joining the Arthritis Foundation in 2014, Anna worked as Senior Manager for Federal Affairs at the American Congress of Obstetricians and Gynecologists, where she managed a portfolio of issues including appropriates, physician workforce, and health IT. She began her health policy career as a Congressional Fellow for Energy and Commerce Committee members, where she drafted legislation and staffed Committee activities. Anna received her BA in History from Southern Methodist University, and taught junior high and high school history before moving to Washington, D.C. in 2007 to pursue an MA in Political Science from American University.
Bruny Kenou
George Washington School of Medicine and Health Sciences
Bruny Kenou
Bruny Kenou is a dedicated mental health activist and a medical student at the George Washington School of Medicine and Health Sciences after graduating with Distinction in Neuroscience from Duke University in 2020,
Bruny’s passion for mental health is evident through her research roles at the National Institutes of Mental Health (NIMH) and the Duke Institute of Brain Sciences. At NIMH, she delved into groundbreaking work in a Molecular Neuroimaging lab, focusing on radiotracer research for neurodegenerative and neuropsychiatric diseases.
As an advocate, Bruny has served in several advising and consulting roles on Youth Mental Health for organization such as the National Alliance on Mental Illness (NAMI) and co-founded DukeLine, a virtual peer-to-peer mental health support program. Her commitment to technology-driven behavioral health improvements led her to volunteer as a Data Analyst at Lean On Me.
In 2020, Bruny founded Lay Mental Health Advocates, emphasizing community psychoeducation and virtual patient advocacy for enhanced community mental health. She also serves as an advisor to NAMI, one of the largest Mental Health Advocacy Organizations in the US.
Throughout her medical journey, Bruny aims to champion social and medical justice, aspiring to become a physician, researcher, policymaker, and public health official. She hopes to continue advancing health equity as a future physician, policymaker, and public health official.
Barry Liden
USC Schaeffer Center
Barry Liden, JD
Barry Liden is Director of Public Policy for the USC Schaeffer Center for Health Policy and Economics, helping measurably improve value in health through evidence-based policy solutions, research excellence, and private and public-sector engagement.
Before joining USC in 2022, Liden served as a medical device industry executive at Edwards Lifesciences for almost two decades. His career there culminated as Vice President of Patient Engagement where he created a new function to engage with, learn from and empower patients to improve the healthcare experience. Liden joined Edwards in 2002 as Director of Global Communications, and served in several public affairs positions, including Vice President of Government Affairs.
Liden is also Founder and Managing Advisor of Patient Voice Advisors, a resource hub for organizations seeking to empower patients’ perspectives throughout all phases of health technology innovation.
For more than three decades, Liden has integrated public policy, government relations, public relations and crisis management practices to provide strategic solutions to unique challenges. His passion is to bring novel approaches that can improve the lives of everyone in this global community. He currently serves as a Member of the Maryland Commission on Aging, serves as chair-emeritus in the Medical Device Innovation Consortium’s patient-focused working groups, and serves on the Health Technology Assessment International’s (HTAi) Patient and Community Involvement Working Group Steering Committee.
Liden has a bachelor of science in public administration from the University of Southern California, and a juris doctor from Loyola Law School of Los Angeles. He lives in Garrett Park, Maryland.
Mark Linthicum
Innovation and Value Initiative
Mark Linthicum, MPP
Mark Linthicum, Director of Scientific Communications, brings scientific training and expertise in communications and strategic planning to his role. With over 12 years of health policy and public health experience, he’s conducted policy-facing research in diverse therapeutic areas including oncology, hepatology, infectious disease, and nutrition. Linthicum has been published in leading economics, medicine, and health policy journals including JAMA Oncology, Health Affairs, Chest, and Health Services Research.
Linthicum earned his bachelor’s degree in anthropology from the University of North Carolina at Chapel Hill and his master’s degree in public policy from the University of Southern California.
Karen Mancera-Cuevas
National Health Council
Karen Mancera-Cuevas, DrPH, MPH, MS
Dr. Karen Mancera-Cuevas has a professional background which includes previously working in leadership positions at academic centers emphasizing clinical, public health, and community-based participatory research at the University of Illinois at Chicago and Northwestern University. Additionally, she has engaged with the public in recent state-wide governmental public health efforts in Illinois. Her more than 25 years of professional experience also encompasses varied non-profit and policy-level settings. Programs developed under her leadership addressed chronic disease health disparities in diverse communities of color, specifically targeting women and children at the community-level.
She has Master’s level degrees in Public Administration (MS) and Health Policy (MPH) from DePaul University and the University of Illinois at Chicago. Additionally, she earned her Doctorate of Public Health (DrPH) from Walden University and is a Certified Health Education Specialist (CHES). Dr. Mancera-Cuevas is Chair-Elect, Program Committee Member and Policy Reviewer for the Public Health Education and Health Promotion Section of the American Public Health Association (APHA), a delegate to the Coalition for National Health Education Organizations (CNHEO), is Associate Editor of Progress in Community Health Partnerships (PCHP) and Regional Committee Trustee for the International Union for Health Promotion and Education (IUHPE).
Dr. Mancera-Cuevas is of Colombian/Chilean descent, she enjoys spending time with her family, doing gardening, yoga and crafting in her free time. She is also a mom of four pets (a cat, dog, and two birds).
Michael Mersky
OPEN Health
Michael Mersky
Elridge Proctor
GO2 for Lung Cancer
Elridge D. Proctor, MPA
Rhonda Robinson Beale
UnitedHealth Group
Rhonda Robinson Beale, MD
Dr. Robinson Beale has served on many national boards, engaged with key committees and workgroups and has been significantly involved in influencing changes in the system. She was on the IOM committee that created “Crossing the Quality Chasm and “To Err is Human.” Dr. Robinson Beale has been involved in influencing local and national legislation particularly around Parity and ACA issues. Her involvements led to her having the opportunity to testify before the Senate’s Health, Education, Labor and Pension Committee (HELP) on the state of behavioral health care.
Richard Schmitz
Pharmacy Quality Alliance
Richard Schmitz, MA
Schmitz has 20 years of experience translating complex issues into compelling messages, engaging stakeholders and creating effective strategies for change. Prior to joining PQA, Schmitz led the health care public affairs group for the Washington, D.C., office of the international PR firm Golin, where he advised clients on strategic corporate communications, stakeholder engagement, public affairs and government relations. Before that, he was director of communications for the Society for Women’s Health Research and director of public relations at NAADAC, The Association for Addiction Professionals.
Jason Spangler
Innovation and Value Initiative
Jason Spangler, MD, MPH, FACPM
For nearly two decades, Dr. Spangler, IVI’s Chief Executive Officer, has worked in the professional health policy and public health sector with pharmaceutical and non-profit organizations. Dr. Spangler joins IVI from his most recent role as Executive Medical Director and Director and Head of Global HTA Policy Strategy and Engagement for Amgen, Inc.
Dr. Spangler earned his MD at the Pennsylvania State University College of Medicine in 1998 and his Master of Public Health from Johns Hopkins Bloomberg School of Public Health in 2002. His commitment to public health, preventive medicine, and health equity date back to his medical school residency, during which he served as a medical team leader for free clinics in Cost Rica, a resident coordinator for free clinics for homeless around UPMC, and a clinical educator in the International Medical Corps in Kosovo.
After serving one year as Chief Resident, Dr. Spangler joined Pfizer Global Pharmaceuticals as a Public Health and Health Policy Consultant. He remained in this role for three years and then moved on to the Partnership for Prevention, where he started as a Managing Senior Fellow and was promoted to Chief Medical Officer until he was recruited to Amgen.
Warren Stevens
Medicus Economics, LLC
Warren Stevens, PhD
Michael Thompson
National Alliance of Healthcare Purchaser Coalitions
Michael Thompson
Michael Thompson is President and CEO of the National Alliance of Healthcare Purchaser Coalitions (National Alliance). The National Alliance is the only non-profit, purchaser-led organization with a national and regional structure dedicated to driving health and healthcare value across the country. Its members represent more than 12,000 employers/purchasers and 45 million Americans spending over $300 billion annually on healthcare. Thompson is a nationally recognized thought leader for business health strategies and health system reform. He has worked with major employers and other stakeholders on a variety of issues and strategies and is known for developing, promoting and leading collaborative cross-sector health industry initiatives.
Prior to joining the National Alliance, Mike was a Principal at PricewaterhouseCoopers (PwC) for 20 years working with employers and other stakeholders and served as an executive with diverse roles with Prudential Healthcare for over 17 years. Mike is a Fellow of the Society of Actuaries, serving on the Health Practice Council, and chair of the Medicare Sub-Committee of the American Academy of Actuaries (AAA). He is also widely recognized as a leading national advocate for mental health and wellbeing and previously served as President of the New York City chapter of the National Alliance for Mental Illness (NAMI). Mike also served as an active member of the board of the Northeast Business Group on Health for 11 years.
Tamar Thompson
Alexion
Tamar Thompson
Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University. Tamar also serves on the board of directors for MassBio Board, the Boston Chamber, and sits on the Schwartz Center (MassGeneral Hospital) Leadership Council.
Norris Turner
Turner Healthcare Quality Consulting, Inc.
Norris Turner, PharmD, PhD
Norris Turner is the President and Chief Executive Officer of Turner Healthcare Quality (THCQ) Consulting, Inc. THCQ Consulting helps biopharmaceutical companies gain marketplace insights, optimize their strategy, and align with their provider and payer customers who are on a shared mission of better patient outcomes, improving patient and provider experiences, reducing cost of care, and advancing health equity. Norris leads the THCQ Consulting team in engagement with clients to bring an integrated understanding and reframed perspective to the most complex and persistent challenges facing biopharmaceutical companies today.
For over twenty years, Norris worked in the biopharmaceutical industry as an executive for Pfizer, Purdue Pharma, and Johnson & Johnson. His vast industry experience stretches across clinical development, medical affairs, and market access/health care quality. Prior to launching THCQ Consulting, Inc., Norris worked as a senior executive at a non-profit, quality measure development organization, Pharmacy Quality Alliance (PQA), in the Washington D.C. area. In this role, Norris led efforts involving a diverse range of healthcare stakeholders and organizations that included commercial and public payers, technology vendors, pharmacy, and biopharmaceutical companies.
His extensive professional background and education includes doctoral degrees in clinical pharmacy (Pharm D.) from The University of Michigan and pharmaceutical chemistry (Ph.D.) from the University of California San Francisco. Norris did a postdoctoral research fellowship in molecular pharmacology from Stanford University School of Medicine. He also has a Health Policy Educational Certificate from Thomas Jefferson University School of Population Health.
Norris served on the University of Michigan College of Pharmacy Dean’s Advisory Committee. He is currently a member of the Board of Directors for the non-profit organization, National Transitions of Care Coalition (NTOCC).
Norris was honored as a 2016 PhRMA We Work For Health Champion.
He lives in Yardley, Pennsylvania with his wife and has three grown children.
Gretchen Wartman
National Minority Quality Forum
Gretchen Wartman
Gretchen Clark Wartman is Vice President for Policy and Program of the National Minority Quality Forum (NMQF), and Director of the NMQF Institute for Equity in Health Policy and Practice. Ms. Wartman also directs the NMQF National Alliance for Brain Health and Awareness. Ms. Wartman has more than 40 years of experience in the public and private sectors in health policy strategy and analysis, issue advocacy, and program administration. Prior to her tenure with NMQF, Ms. Wartman held positions with the Missouri Department of Health and Senior Services, including serving as the Title V/Maternal and Child Health Director, and Director of the Division of Nutritional Health and Services. Ms. Wartman is a Peer Reviewer for the Journal of Healthcare, Science and The Humanities.
Richard Xie
Innovation and Value Initiative
Richard Xie, PhD
Richard Xie is a health economist and serves as Director of Research. He has a track record of conducting studies in health economics and outcomes research (HEOR) to inform health policy design and evaluation of health care interventions. Formerly, he was a consultant at the Analysis Group, managing a portfolio of studies to demonstrate the value of novel therapies for pharmaceutical clients. Xie was also a health policy researcher at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California, examining policy questions in medication non-adherence, health disparities, and healthcare innovation. His work has been published in leading journals, including Journals of the American College of Cardiology, Journal of General Internal Medicine, and PLOS One.
Xie earned his doctorate in economics from the University of Southern California.